Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 14, 2012Journal of Clinical Oncology

Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

SBSebastian BöttcherUniversity of RostockMRMatthias RitgenUniversity Hospital Schleswig-HolsteinKFKirsten FischerDüsseldorf University Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Böttcher et al. (2012) studied this question.

synapsesocial.com/papers/6a03c3cd94ec7ec37ca9cfd0https://doi.org/10.1200/jco.2011.36.9348
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia2010 · 136 citations
  2. 2Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors2002 · 523 citations
  3. 3Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia2006 · 389 citations
  4. 4Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia2008 · 323 citations
  5. 5Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia2008 · 693 citations